RARE Ultragenyx
Company Analysis
Latest News
Ultragenyx's Angelman Drug Fails Its Biggest Test — Now What Is Left to Support a $1.4 Billion Company?
Shares of Ultragenyx Pharmaceutical cratered 45% overnight after its most-watched experimental therapy — a gene-silencing drug for Angelman syndrome, a rare...
🔴 Ultragenyx is trading 45.53% down in pre-market after Phase 3 Aspire study failed primary endpoints
Ultragenyx is trading at $14.45 (-45.53%) in pre-market after its Phase 3 Aspire study of apazunersen failed to meet primary and key secondary endpoints. -...
Ultragenyx's Phase 3 Angelman Syndrome Trial for Apazunersen Fails to Meet Endpoints
Ultragenyx Pharmaceutical Inc. announced that its Phase 3 Aspire study for apazunersen (GTX-102) in patients with Angelman syndrome did not meet its primary or...
🔴 Ultragenyx is trading 43% down in after-hours trading
Ultragenyx is trading 42.82% down at $15.17 after-hours on September 2, 2026, versus the regular-session close; the catalyst remains unclear. - No credible...
🟢 Ultragenyx is trading 4.1% up today after GENGLYCOS FDA approval
Ultragenyx is trading at $26.79 (+4.14%) after the August 19 FDA approval of GENGLYCOS, its first approved gene therapy. - Reuters reported the announcement...
🟢 Ultragenyx is trading 4.64% up today after FDA’s accelerated approval of GENGLYCOS
Ultragenyx is trading 4.64% up now at $26.50 as investors continue responding to the FDA’s accelerated approval of GENGLYCOS, announced August 19, 2026. - The...
🔴 Ultragenyx is trading 4.23% down today amid broader biotech pullback
Ultragenyx is trading 4.23% down at $25.13 amid a broader biotech pullback and weak risk sentiment across U.S. equities. - Ultragenyx announced accelerated...
Ultragenyx Stock Falls, Awaiting FDA Decision on Rare Disease Gene Therapy
Ultragenyx Pharmaceutical (RARE) shares fell for a second consecutive day on Tuesday, August 18th. Investors are awaiting an FDA decision on DTX401, a gene...
Ultragenyx Lands Its First Gene Therapy — But Can a Tiny Patient Pool Justify the Stock's Leap of Faith?
Shares of Ultragenyx surged 14% to $29.91 after the FDA granted accelerated approval for the company's first-ever gene therapy, a one-time treatment for a rare...
🟢 Ultragenyx is trading 13.99% up in pre-market after FDA granted accelerated approval for GENGLYCOS
Ultragenyx is trading 13.99% up at $29.91 after FDA granted accelerated approval for GENGLYCOS on August 19, 2026. - GENGLYCOS treats glycogen storage disease...
Ultragenyx Receives FDA Accelerated Approval for GSDIa Gene Therapy GENGLYCOS™
Ultragenyx Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for its gene therapy, GENGLYCOS™...
🟢 Ultragenyx is trading 10% up in after-hours trading with no verified company-specific catalyst
Ultragenyx is trading 10% up at $28.86 after closing at $26.24 on August 19, 2026, with no verified company-specific announcement released after the regular...
🔴 Ultragenyx is trading 4.1% down today as higher yields pressure biotech stocks
Ultragenyx is trading 4.1% down now at $25.07, primarily as higher yields and broader risk-off trading pressure growth-oriented biotechnology stocks. - No...
Ultragenyx Settles DOJOLVI® Patent Litigation, Allows Generic Entry in 2033
Ultragenyx Pharmaceutical Inc. has entered into a settlement agreement with Esjay Pharma to resolve patent litigation related to its drug, DOJOLVI®...
🟢 Ultragenyx is trading 4% up today after record Q2 results beat estimates
Ultragenyx is trading 4.01% up now at $26.95 after investors continued reacting to its record second-quarter results. - Q2 revenue reached $214 million,...
Ultragenyx Posts Its Best Quarter Ever, But Can a Still-Unprofitable Biotech Turn a Revenue Beat Into a Real Turnaround?
Shares of Ultragenyx Pharmaceutical shifted sharply higher after the rare-disease drugmaker delivered a blowout second quarter that caught Wall Street off...
Ultragenyx Posts Its Best Quarter Ever, But Can a Still-Unprofitable Biotech Turn a Revenue Beat Into a Real Turnaround?
Shares of Ultragenyx Pharmaceutical shifted sharply higher after the rare-disease drugmaker delivered a blowout second quarter that caught Wall Street off...
🟢 Ultragenyx is trading 4.6% up today after record Q2 revenue beat
Ultragenyx is trading 4.6% up now at $26.07 after investors continued reacting to its August 4 earnings release and record second-quarter revenue. -...
🔴 Ultragenyx is trading 4.1% down today on post-earnings profit-taking
Ultragenyx is trading 4.1% down at $24.77 today as the stock undergoes a typical post-earnings reversal following yesterday's significant rally. • The company...
🟢 Ultragenyx is trading 4.1% up today after record Q2 revenue and earnings beat
Ultragenyx is trading 4.1% up at $25.57 after reporting record second-quarter revenue that significantly exceeded Wall Street expectations. • The company...